CH Biotech R&D Co., Ltd.
CH Biotech R&D Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of agriculture chemicals in Taiwan, the United States, and internationally. It offers fertilizers and plant growth regulators; and provides biotechnology services. The company was incorporated in 2013 and is headquartered in Nantou City, Taiwan.
CH Biotech R&D Co., Ltd. (6534) - Total Assets
Latest total assets as of September 2025: NT$3.68 Billion TWD
Based on the latest financial reports, CH Biotech R&D Co., Ltd. (6534) holds total assets worth NT$3.68 Billion TWD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
CH Biotech R&D Co., Ltd. - Total Assets Trend (2020–2024)
This chart illustrates how CH Biotech R&D Co., Ltd.’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
CH Biotech R&D Co., Ltd. - Asset Composition Analysis
Current Asset Composition (December 2024)
CH Biotech R&D Co., Ltd.'s total assets of NT$3.68 Billion consist of 23.5% current assets and 76.5% non-current assets.
| Asset Category | Amount (TWD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 13.2% |
| Accounts Receivable | NT$164.00 Million | 4.5% |
| Inventory | NT$117.10 Million | 3.2% |
| Property, Plant & Equipment | NT$0.00 | 0.0% |
| Intangible Assets | NT$3.43 Million | 0.1% |
| Goodwill | NT$2.45 Million | 0.1% |
Asset Composition Trend (2020–2024)
This chart illustrates how CH Biotech R&D Co., Ltd.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: CH Biotech R&D Co., Ltd.'s current assets represent 23.5% of total assets in 2024, an increase from 15.4% in 2020.
- Cash Position: Cash and equivalents constituted 13.2% of total assets in 2024, up from 11.3% in 2020.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2020.
- Asset Diversification: The largest asset category is accounts receivable at 4.5% of total assets.
CH Biotech R&D Co., Ltd. Competitors by Total Assets
Key competitors of CH Biotech R&D Co., Ltd. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Nanjing Red Sun Co Ltd
SHE:000525
|
China | CN¥6.84 Billion |
|
ADAMA Ltd
SHE:000553
|
China | CN¥49.93 Billion |
|
Grand Industrial Holding Co Ltd
SHE:000626
|
China | CN¥8.43 Billion |
|
Qinghai Salt Lake Industry Co.Ltd
SHE:000792
|
China | CN¥50.97 Billion |
|
Sichuan Meifeng Chemical Industry Co Ltd
SHE:000731
|
China | CN¥5.17 Billion |
|
Asia Potash International Investment Guangzhou Co Ltd
SHE:000893
|
China | CN¥19.38 Billion |
|
Hubei Xinyangfeng Fertilizer Co Ltd
SHE:000902
|
China | CN¥19.75 Billion |
|
Sichuan Lutianhua Co Ltd
SHE:000912
|
China | CN¥9.46 Billion |
CH Biotech R&D Co., Ltd. - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - CH Biotech R&D Co., Ltd. generates 0.45x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Excellent ROA - For every $100 in assets, CH Biotech R&D Co., Ltd. generates $ 13.13 in net profit.
CH Biotech R&D Co., Ltd. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.15 | 1.39 | 1.36 |
| Quick Ratio | 1.04 | 1.27 | 1.21 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | NT$129.07 Million | NT$ 227.43 Million | NT$ 323.03 Million |
CH Biotech R&D Co., Ltd. - Advanced Valuation Insights
This section examines the relationship between CH Biotech R&D Co., Ltd.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.36 |
| Latest Market Cap to Assets Ratio | 0.03 |
| Asset Growth Rate (YoY) | -0.5% |
| Total Assets | NT$3.63 Billion |
| Market Capitalization | $93.83 Million USD |
Valuation Analysis
Below Book Valuation: The market values CH Biotech R&D Co., Ltd.'s assets below their book value (0.03 x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: CH Biotech R&D Co., Ltd.'s assets decreased by 0.5% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for CH Biotech R&D Co., Ltd. (2020–2024)
The table below shows the annual total assets of CH Biotech R&D Co., Ltd. from 2020 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | NT$3.63 Billion | -0.55% |
| 2023-12-31 | NT$3.65 Billion | +14.21% |
| 2022-12-31 | NT$3.20 Billion | +5.50% |
| 2021-12-31 | NT$3.03 Billion | +5.19% |
| 2020-12-31 | NT$2.88 Billion | -- |